| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3946893 | Gynecologic Oncology | 2012 | 5 Pages |
Purpose/objective(s)To determine the prognostic significance of time to recurrence (TTR) on overall survival (OS) and disease-specific survival (DSS) following recurrence in patients with stage I–II uterine endometrioid carcinoma.Materials/methodsAfter IRB approval, we retrospectively identified 57 patients with recurrent endometrioid carcinoma who were initially treated for FIGO 1988 stages I–II between 1987 and 2009. The Kaplan–Meier approach and Cox regression analysis were used to estimate OS and DSS following recurrence and identify factors impacting outcomes.ResultsMedian follow-up times were 54.8 months from hysterectomy and 19.8 months after recurrence. Median time to recurrence was 20.2 months. Twenty-eight (47%) patients had a recurrence < 18 months after hysterectomy and 29 (53%) had a recurrence ≥ 18 months. Both groups were evenly matched regarding initial pathological features and adjuvant treatments. The median OS and DSS in patients with TTR < 18 months was shorter than those with TTR ≥ 18 months, but not statistically significant (p = 0.216). TTR did not impact outcomes after loco-regional recurrence, but for extrapelvic recurrence, a shorter TTR resulted in worse OS and DSS (p = 0.03). On multivariate analysis, isolated loco-regional recurrence (HR 0.28, p = 0.001) and salvage radiation therapy (HR 0.47, p = 0.045) were statistically significant independent predictors of longer OS following recurrence. TTR as a continuous variable or dichotomized was not predictive of OS or DSS.ConclusionsIn our study, the prognostic impact of time to recurrence was less important than the site of recurrence. While not prognostic for the entire cohort or for patients with loco-regional recurrence, TTR < 18 months was associated with shorter OS and DSS after extrapelvic recurrence.
► The prognostic impact of time to recurrence was less important than the site of recurrence. ► Time to recurrence less than 18 months was associated with shorter overall and disease-specific survival after extrapelvic recurrence.
